ORKA

Oruka Therapeutics, Inc. ORKA

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-41.21M

Quarter to Jun 30

Free cash flow

$-33.15M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$7.05B total
FMR LLC
$862.02M+21.9%
BlackRock, Inc.
$474.92M+41.5%
VR Adviser, LLC
$394.81M0.0%
Fairmount Funds Management LLC
$352.63M0.0%
Capital World Investors
$323.73MNew
RTW INVESTMENTS, LP
$298.74M+52.5%
STATE STREET CORP
$254.38M+65.7%
VANGUARD CAPITAL MANAGEMENT LLC
$224.69M+27.0%
Paradigm Biocapital Advisors LP
$204.09M-7.6%
Deep Track Capital, LP
$183.30M-5.3%
Bellevue Group AG
$157.71M+226.9%
FRANKLIN RESOURCES INC
$154.31M+61.5%
Remedium Capital Partners, LLC
$149.00M-17.1%
RA CAPITAL MANAGEMENT, L.P.
$147.95MNew
VIKING GLOBAL INVESTORS LP
$143.09M-43.6%
GEODE CAPITAL MANAGEMENT, LLC
$136.11M+49.8%
Jupiter Topco LLC
$130.97M--
PERCEPTIVE ADVISORS LLC
$128.01M-3.6%
Polar Capital Holdings Plc
$116.93M+17.3%
CITADEL ADVISORS LLC
$106.50M+11.1%
T. Rowe Price Investment Management, Inc.
$105.04MNew
BNP PARIBAS FINANCIAL MARKETS
$102.69M+9773.9%
PRICE T ROWE ASSOCIATES INC /MD/
$79.81M+15.3%
Avidity Partners Management LP
$72.37M0.0%
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC
$62.65MNew
See all 257 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ORKA

Earnings Per Share

13fpro.ai/company/ORKA

Loading ratio trend…

ORKA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Oruka Therapeutics, Inc. (ORKA): stock profile, AI score and financials

Oruka Therapeutics, Inc. (ORKA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ORKA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Oruka Therapeutics, Inc. reports net income of $-41.2M, free cash flow of $-33.1M. ORKA trades on the Nasdaq exchange and files with the SEC under CIK 907654. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORKA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Oruka Therapeutics, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 907654 →